What is PhaseV?
PhaseV is at the forefront of clinical trial innovation, employing sophisticated algorithms such as reinforcement learning and causal machine learning. Its technology is designed to enhance adaptive trial design and enable closed-loop execution, thereby improving trial success rates while optimizing resource allocation and time efficiency. The company's unique methodology and advanced technological capabilities allow for the identification of subtle data signals and the extraction of actionable insights from clinical trial results.
How much funding has PhaseV raised?
PhaseV has raised a total of $65M across 2 funding rounds:
Other Financing Round
$15M
Series A
$50M
Other Financing Round (2023): $15M with participation from Exor Ventures, LionBird, and Viola Ventures
Series A (2025): $50M led by Viola Ventures, Insight Partners, LionBird, EXOR, and Accel
Key Investors in PhaseV
Exor Ventures
Exor Ventures is a venture capital firm based in Ireland, likely focusing on early-stage investments within the technology sector.
LionBird
LionBird is a venture capital firm specializing in innovative health-tech startups, providing pre-scale capital and strategic support to transform healthcare solutions.
Insight Partners
Insight Partners is a global venture capital and private equity firm that invests in high-growth software and technology companies, assisting them in scaling from early stage to IPO.
What's next for PhaseV?
With this recent major strategic investment, PhaseV is poised to accelerate its development and market penetration. The capital will likely fuel further research and development into its adaptive trial design technologies, expand its operational capacity, and strengthen its market presence. The company's focus on efficiency and data-driven insights positions it to address critical challenges in the pharmaceutical and biotechnology sectors, potentially leading to faster drug development cycles and improved patient outcomes.
See full PhaseV company page
